ArticleFrontiers in medicine2023
Artificial intelligence-supported web application design and development for reducing polypharmacy side effects and supporting rational drug use in geriatric patients.
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Current perspectives and emerging directions in research and practice: highlights from the 15th Annual International Workshop on Aging and HIV.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- The Role of Artificial Intelligence in Medication Management for Older Adults: A Systematic Review.Aging medicine (Milton (N.S.W)) · 2026Review
- Artificial intelligence-driven risk prediction of polypharmacy in older adults: current advances, clinical applications, and future perspectives.Frontiers in public health · 2026Review
- Analytical approaches for medication management for patient safety: a scoping review.npj health systems · 2025Article
- Smart aging: integrating AI into elderly healthcare.BMC geriatrics · 2025Review
- Assessing potentially inappropriate medication use among older adults in Central and Eastern Europe.Annals of medicine · 2025Article
- Artificial Intelligence in Medication Management for Older Adults in Low- and Middle-Income Countries: A Narrative Review.Aging medicine (Milton (N.S.W)) · 2025Review
- AI and Primary Care: Scoping Review.Journal of medical Internet research · 2025Article
- Artificial Intelligence in the Management of Polypharmacy Among Older Adults: A Scoping Review.Cureus · 2025Review
- Employing bibliometrics and natural language processing (NLP) to analyse real-world applications of adverse drug reaction.Exploratory research in clinical and social pharmacy · 2025Article
- A Critical Review of the Prospect of Integrating Artificial Intelligence in Infectious Disease Diagnosis and Prognosis.Interdisciplinary perspectives on infectious diseases · 2025Review
- Evaluating the Capabilities of Generative AI Tools in Understanding Medical Papers: Qualitative Study.JMIR medical informatics · 2024Article
- Defining, identifying and addressing problematic polypharmacy within multimorbidity in primary care: a scoping review.BMJ open · 2024Article
- Potential Applications of Artificial Intelligence (AI) in Managing Polypharmacy in Saudi Arabia: A Narrative Review.Healthcare (Basel, Switzerland) · 2024Review
- Digital Technology Applications in the Management of Adverse Drug Reactions: Bibliometric Analysis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Evolutionary trend analysis of the pharmaceutical management research field from the perspective of mapping the knowledge domain.Frontiers in health services · 2024Review
- The Prevalence of Potentially Inappropriate Prescribing in Two Family Health Units in Portugal.Cureus · 2023Article
- Enhancing Primary Care for Nursing Home Patients with an Artificial Intelligence-Aided Rational Drug Use Web Assistant.Journal of clinical medicine · 2023Article
- Leveraging artificial intelligence to combat antimicrobial resistance in geriatric care.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The main complications of polypharmacy, which is known as the simultaneous use of more than five drugs, are potentially inappropriate medicines(PIMs), drug-drug, and drug-disease interaction. It is aimed to prepare an auxiliary tool to reduce the complications of polypharmacy and to support rational drug use(RDU), by evaluating the patient with age, drugs, and chronic diseases in this study. Materials and methods: In the first phase of this study, as methodological research, an up-to-date and comprehensive auxiliary tool as a reference method was generated with a database containing interaction information of 430 most commonly used drug agents and chronic diseases in geriatrics in the light of current and valid 6 PIM criteria for geriatric patients, and medication prospectuses, relevant current articles, and guidelines. Then, an artificial intelligence(AI) supported web application was designed and developed to facilitate the practical use of the tool. Afterward, the data of a cross-sectional observational single-center study were used for the rate and time of PIM and drug interaction detection with the web application. The proposed web application is publicly available at https://fastrational.com/. Results: While the PIM coverage rate with the proposed tool was 75.3%, the PIM coverage rate of EU(7)-PIM, US-FORTA, TIME-to-STOPP, Beers 2019, STOPP, Priscus criteria in the web application database respectively(63.5%-19.5%) from the highest to the lowest. The proposed tool includes all PIMs, drug-drug, and drug-disease interaction information detected with other criteria. A general practitioner detects interactions for a patient without the web application in 2278 s on average, while the time with the web application is decreased to 33.8 s on average, and this situation is statistically significant. Discussion: In the literature and this study, the PIM criteria alone are insufficient to include actively used medicines and it shows heterogeneity. In addition, many studies showed that the biggest obstacle to drug regulation in practice is "time constraints." The proposed comprehensive auxiliary tool analyzes age, drugs, and diseases specifically for the patient 60 times faster than the manual method, and it provides quick access to the relevant references, and ultimately supports RDU for the clinician, with the first and only AI-supported web application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.